

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
17 July 2003 (17.07.2003)

PCT

(10) International Publication Number
WO 03/057154 A2

(51) International Patent Classification⁷:

A61K

(74) Agents: BENT, Stephen, A. et al.; Foley & Lardner, Washington Harbour, 3000 K Street, N.W., Suite 500, Washington, DC 20007-5143 (US).

(21) International Application Number: PCT/US02/41571

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:

27 December 2002 (27.12.2002)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/342,770 28 December 2001 (28.12.2001) US

(71) Applicant (*for all designated States except US*): **GUILDFORD PHARMACEUTICALS INC.** [US/US]; 6611 Tributary Street, Baltimore, MD 21224 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **SLUSHER, Barbara, S.** [US/US]; 7424 Longfield Drive, Kingsville, MD 21087 (US). **WOZNIAK, Krystyna** [US/US]; 422 Fox Catcher Road, Bel Air, MD 21015 (US).


Published:

— without international search report and to be republished upon receipt of that report

[Continued on next page]

(54) Title: NAALADASE INHIBITORS FOR TREATING HUNTINGTON'S DISEASE

Rotarod Tests on Transgenic HD Mice After the Treatments With Compound B (30 mg/kg/day, orally)



- HD+Compound B
- ▨ HD+Vehicle
- Normal+Compound B
- ▨ Normal+Vehicle

WO 03/057154 A2

(57) Abstract: This invention relates to a pharmaceutical composition and a method for treating Huntington's disease using NAAL-ADase inhibitors.